Table 4 Adjusted odds ratios (OR) and 95% confidence intervals (CI) of the presence of hyperuricemia associated with the visceral adiposity index, along with metabolic health and obesity phenotypes defined by ATP-III and HOMA criteria, respectively.

From: Visceral adiposity index is strongly associated with hyperuricemia independently of metabolic health and obesity phenotypes

 

Model 1

ATP-III criteria

HOMA criteria

Model 2

Model 3

Model 2

Model 3

Visceral adiposity index

1st Quartile

1 (Ref)

1 (Ref)

1 (Ref)

1 (Ref)

1 (Ref)

2nd Quartile

1.41 (1.16–1.73)

1.36 (1.11–1.66)

1.3 (1.06–1.59)

1.36 (1.11–1.66)

1.29 (1.06–1.58)

3rd Quartile

2.29 (1.90–2.76)

1.95 (1.60–2.38)

1.77 (1.45–2.17)

2.03 (1.67–2.46)

1.85 (1.52–2.24)

4th Quartile

6.93 (5.79–8.29)

4.88 (3.92–6.09)

4.38 (3.49–5.49)

5.65 (4.68–6.82)

5.07 (4.18–6.14)

Obesity phenotype

MHNO

1 (Ref)

1 (Ref)

1 (Ref)

1 (Ref)

MUNO

1.29 (1.08–1.54)

1.27 (1.05–1.54)

1.44 (1.20–1.72)

1.54 (1.27–1.87)

MHO

1.19 (0.96–1.48)

1.11 (0.89–1.38)

1.25 (1.06–1.47)

1.16 (0.98–1.38)

MUO

1.93 (1.59–2.35)

1.78 (1.43–2.20)

2.16 (1.79–2.60)

2.07 (1.69–2.53)

  1. Abbreviations: ATP-III, the Adult Treatment Panel-III; HOMA, homeostasis model assessment of insulin resistance; MHNO, metabolically healthy non-obese; MUNO, metabolically unhealthy non-obese; MHO, metabolically healthy obese; and MUO, metabolically unhealthy obese. Model 1: Adjusted for age and sex. Model 2: Adjusted for Model 1 + urban/rural resident, smoking status, alcohol status and metabolic health-obesity phenotypes. Model 3: Adjusted for Model 2 + white blood cell, total cholesterol, blood pressure, glucose and hs-CR.